Shriwas Omprakash, Mohapatra Pallavi, Mohanty Sibasish, Dash Rupesh
Institute of Life Sciences, Bhubaneswar, India.
Manipal Academy of Higher Education, Manipal, India.
Front Oncol. 2021 Feb 25;10:612337. doi: 10.3389/fonc.2020.612337. eCollection 2020.
m6A RNA methylation, which serves as a critical regulator of transcript expression, has gathered tremendous scientific interest in recent years. From RNA processing to nuclear export, RNA translation to decay, m6A modification has been studied to affect various aspects of RNA metabolism, and it is now considered as one of the most abundant epitranscriptomic modification. RNA methyltransferases (writer), m6A-binding proteins (readers), and demethylases (erasers) proteins are frequently upregulated in several neoplasms, thereby regulating oncoprotein expression, augmenting tumor initiation, enhancing cancer cell proliferation, progression, and metastasis. Though the potential role of m6A methylation in growth and proliferation of cancer cells has been well documented, its potential role in development of therapy resistance in cancer is not clear. In this review, we focus on m6A-associated regulation, mechanisms, and functions in acquired chemoresistance, radioresistance, and resistance to immunotherapy in cancer.
N6-甲基腺苷（m6A）RNA甲基化作为转录本表达的关键调节因子，近年来引起了科学界的极大兴趣。从RNA加工到核输出，从RNA翻译到降解，人们已经研究了m6A修饰对RNA代谢各个方面的影响，现在它被认为是最丰富的表观转录组修饰之一。RNA甲基转移酶（写作者）、m6A结合蛋白（阅读者）和去甲基化酶（擦除者）蛋白在几种肿瘤中经常上调，从而调节癌蛋白表达、促进肿瘤起始、增强癌细胞增殖、进展和转移。尽管m6A甲基化在癌细胞生长和增殖中的潜在作用已有充分记载，但其在癌症治疗耐药性发展中的潜在作用尚不清楚。在这篇综述中，我们聚焦于m6A在癌症获得性化疗耐药、放疗抵抗和免疫治疗抵抗中的相关调节、机制及功能。
